Walleye Capital LLC Immuno Gen, Inc. Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $1.39 Million - $3.35 Million	111,863 New	111,863 $3.32 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $405,000 - $2.17 Million	108,000 New	108,000 $2.04 Million
Q2 2022 Aug 08, 2022	BUY	$3.15 - $5.76 $499,848 - $914,008	158,682 Added 280.77%	215,198 $968,000
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $122,074 - $214,346	28,656 Added 102.86%	56,516 $269,000
Q4 2021 Mar 03, 2022	BUY	$4.75 - $7.5 $132,335 - $208,950	27,860 New	27,860 $206,000
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $77,701 - $125,875	-11,954 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $44,229 - $91,567	11,954 New	11,954 $77,000
Q1 2020 May 15, 2020	SELL	$2.12 - $6.8 $138,355 - $443,781	-65,262 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.25 - $5.8 $70,600 - $181,992	-31,378 Reduced 32.47%	65,262 $333,000
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $125,740 - $192,009	56,640 Added 141.6%	96,640 $234,000
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $72,000 - $132,000	40,000 New	40,000 $87,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.